We welcome your feedback and / or questions related to the
educational content provided through Mechanisms in Fungal Infections.
Release date:
January 19, 2009
Expiration date:
January 19, 2010
Click here to view Technical Requirements
Accreditation
This learning activity has been designated to a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Target Audience
This learning activity is intended for oncologists, hematologists, infectious disease specialists who treat transplant patients and other patient populations at risk for developing fungal infections.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- Apply the guidelines of the Infectious Diseases Society of America for the treatment of candidemia and acute hematogenously disseminated candidiasis.
- Describe the differing treatment options for stable and unstable moderately severe–to-severely ill patients as well as for patients infected with Candida glabrata and Candida krusei.
- Discuss the value of fluconazole, caspofungin, anidulafungin, micafungin, and amphotericin B compounds in the treatment of candidemia/invasive candidiasis and potential problems for the echinocandins in treating Candida parapsilosis infections.
- Explain that asymptomatic candiduria is not treated while Candida cystitis and pyleonephritis require systemic antifungal agents.
Author
Coleman Rotstein, MD, FRCPC
Professor of Medicine
University of Toronto
Division of Infectious Diseases
University Health Network
Toronto, Ontario
Medical Writers
Karla Badger-Brown
Toronto, ON
Laurel McKee Ranger
Randolph, NJ
Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.
All authors were independently selected by the organizing committee. Those authors who disclosed affiliations or financial interests with the commercial organizations involved with products, to which the may refer are listed below.
1 = grant research
2 = consultant
3 = speaker’s bureau
4 = stock shareholder
5 = other support
Dr. Coleman Rotstein
Supporters of this activity:
Astellas Pharma US, Inc.1,2,3
Pfizer Inc1,2,3
Other affiliations:
Basilea Pharmaceutica Ltd.1
MERCK & CO., Inc.2,3
Medical Writers
Karla Badger-Brown
Does not report any affiliations with commercial organizations.
Laurel McKee Ranger
Does not report any affiliations with commercial organizations.
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.
Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
Statement of Commercial Support
The following companies have provided unrestricted educational grants in support of this activity: Astellas Pharma US, Inc. and Pfizer Inc.
(*Please check this box to proceed - required)
|